Side Effects of mRNA-Based and Viral Vector-Based COVID-19 Vaccines among German Healthcare Workers

5 Oct 2021

Authors: KLUGAR Miloslav, RIAD Abanoub, MEKHEMAR Mohamed, CONRAD Jonas, BUCHBENDER Mayte, HOWALDT Hans-Peter, ATTIA Sameh


Year of publication 2021
Type Article in Periodical
Magazine / Source Biology
Citation KLUGAR, Miloslav, Abanoub RIAD, Mohamed MEKHEMAR, Jonas CONRAD, Mayte BUCHBENDER, Hans-Peter HOWALDT and Sameh ATTIA. Side Effects of mRNA-Based and Viral Vector-Based COVID-19 Vaccines among German Healthcare Workers. Biology. Basel: MDPI, 2021, vol. 10, No 8, p. 1-21. ISSN 2079-7737. doi:10.3390/biology10080752.
Web https://www.mdpi.com/2079-7737/10/8/752
Doi http://dx.doi.org/10.3390/biology10080752
Keywords adverse effects; BTN162 vaccine; ChAdOx1 COVID-19 vaccine; cross-sectional studies; COVID-19 vaccines; drug-related side effects and adverse reactions; Germany; health personnel; mRNA-1273 vaccine; prevalence

 

Abstract

the increasing number of COVID-19 vaccines available to the public may trigger hesitancy or selectivity towards vaccination. This study aimed to evaluate the post-vaccination side effects of the different vaccines approved in Germany; Methods: a cross-sectional survey-based study was carried out using an online questionnaire validated and tested for a priori reliability. The questionnaire inquired about demographic data, medical and COVID-19-related anamneses, and local, systemic, oral, and skin-related side effects following COVID-19 vaccination; Results: out of the 599 participating healthcare workers, 72.3% were females, and 79.1% received mRNA-based vaccines, while 20.9% received a viral vector-based vaccine. 88.1% of the participants reported at least one side effect. Injection site pain (75.6%) was the most common local side effect, and headache/fatigue (53.6%), muscle pain (33.2%), malaise (25%), chills (23%), and joint pain (21.2%) were the most common systemic side effects. The vast majority (84.9%) of side effects resolved within 1-3 days post-vaccination; Conclusions: the mRNA-based vaccines were associated with a higher prevalence of local side effects (78.3% vs. 70.4%; Sig. = 0.064), while the viral vector-based vaccine was associated with a higher prevalence of systemic side effects (87.2% vs. 61%; Sig. < 0.001). Females and the younger age group were associated with an increased risk of side effects either after mRNA-based or viral vector-based vaccines. The gender- and age-based differences warrant further rigorous investigation and standardized methodology.

Keywords: BTN162 vaccine; COVID-19 vaccines; ChAdOx1 COVID-19 vaccine; Germany; adverse effects; cross-sectional studies; drug-related side effects and adverse reactions; health personnel; mRNA-1273 vaccine; prevalence.

 

For full-text click on the button

Website


More articles

All articles

You are running an old browser version. We recommend updating your browser to its latest version.

More info